Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D
1.4.2026 11:11:00 CEST | Business Wire | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth.
“We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.”
Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Development and Chief Medical Officer, having previously held roles including Chief R&D Officer at OnkosXcel Therapeutics, and CMO roles at MIRNA Therapeutics and Exosome Diagnostics. Additionally, he has held various senior clinical development and medical leadership positions at Sanofi-Aventis, GSK, Genentech and Roche, playing an instrumental role in the development and commercialisation of multiple high-impact oncology therapeutics, including Avastin, Venclexta, Tarceva, Merkinist, and Tafinlar. In early-stage biotech, he has also secured successful public ($420M) and private ($65M series B) financing raises as part of executive leadership teams. He obtained his BSc, MD and MBChB in Medicine from the University of Glasgow.
Vince O’Neill, Head of R&D, Mosaic Therapeutics, commented: “I look forward to working closely with the Board and the team to advance our programs into the clinic and for the opportunity to develop novel combination therapies for cancer patients, utilising innovative biomarker strategies to maximise patient benefit.”
About Mosaic Therapeutics
Mosaic Therapeutics is an oncology therapeutics company building the category leader in Synergistic Precision Oncology. The company’s mission is to tackle cancers with substantial unmet need and few targeted treatment options, by applying its advanced experimental and computational platform to identify oncology combinations that have synergistic activity in biomarker-defined patient populations.
Born out of pioneering research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute, Mosaic has active programs across a variety of oncology indications and disease biology pathways.
The Company’s pipeline is anchored by ASTX295, an MDM2 antagonist, and ASTX029, an ERK1/2 inhibitor, both in-licensed from Astex Pharmaceuticals in April 2025. Mosaic’s first clinical combination study is expected to commence in early 2027.
LinkedIn: https://linkedin.com/company/mosaic-tx
Website: https://mosaic-tx.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260331713463/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 13:00:00 CEST | Press release
The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 11:00:00 CEST | Press release
Expansion builds on North American program success and brings flexible invoicing and net terms to Aventon’s growing retailer network in Europe TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 10:49:00 CEST | Press release
Alpaca has completed its acquisition of European fintech WealthKernel, which will now operate as Alpaca Europe The acquisition gives Alpaca a regulated brokerage and custody presence across the UK and EU Alpaca is also launching European equities trading, beginning with Germany’s Xetra exchange, with Euronext markets and the London Stock Exchange expected to follow Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulato
Comwrap Reply Recognized With the Adobe CXO Emerging Partner Western Europe Award21.4.2026 09:52:00 CEST | Press release
Comwrap Reply, the Reply company specialised in cloud-native digital experience services, has received the Adobe CXO Emerging Partner Western Europe Award, one of the recognitions presented as part of the Adobe Customer Experience Orchestration Partner Awards, which honour companies that have made significant contributions to Adobe’s business and delivered a tangible impact on customer success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421234434/en/ The award is part of a long-standing collaboration with Adobe, recently reaffirmed by the renewal of Comwrap Reply’s Adobe Platinum Solution Partner status, and highlights the experience gained in developing digital experience solutions on Adobe Experience Cloud. The recognition confirms Comwrap Reply’s role in supporting organisations in the design and evolution of digital platforms based on Adobe Experience Cloud, capable of integrating content, data and customer journe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom